Hematopoietic stem cell transplant therapy, clinical trials, complications, and quality of life for patients with Sickle cell anemia: Clinical potential and future perspectives

نویسندگان
verma, Henu kumar ID 1
Lvks, Bhaskar ID 2
Lingojwar, Devendra Purushottam ID 3
Ratre, Yashwant Kumar ID 4
sahu, Tarun ID 5

1 Department of Immunopathology, Institute of lungs Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum, 85764 Neuherberg, Munich, Germany

2 Department of Zoology, Guru GhasidasVishwavidyalaya, Bilaspur, India

3 Regional Society for Education and Research in Community Health, Pune, India

4 Department of Biotechnology, Guru GhasidasVishwavidyalaya, Bilaspur, India.

5 Department of Physiology, AIIMS, Raipur, India

doi
10.18502/ijpho.v12i4.10918
چکیده

Background: Sickle cell anemia (SCA) is an inherited monogenic disorder. The clinical symptoms of SCA are protean, including vaso-occlusion, hemolysis, early stroke, leg ulcers, multi-organ failure, and increased risk of premature death. Hematopoietic stem cell transplantation is the only treatment identified to reduce SCA-related organ damage. Unfortunately, graft rejection is ...

کلیدواژه‌ها
Hemoglobinopathy, Hematopoietic stem-cell transplantation, Quality of Life, Sickle cell Anemia